Esperion Therapeutics Inc

Esperion Therapeutics filed NDSs in Canada for Nexletol and Nexlizet to reduce LDL-C and cardiovascular risk. Nexlizet combines bempedoic acid and ezetimibe. Shares rose 10.7% post-announcement. The drugs are approved in the U.S. and Europe, marketed as Nilemdo and Nustendi ex-U.S. (excluding Japan). Label expansions in 2024 support broader use, with net product sales up 46.2% YOY in 2024. Otsuka Pharmaceutical filed for bempedoic acid in Japan, potentially boosting future sales.

Esperion Therapeutics reports $31.1M in product sales, $20.5M in collaboration revenue, and a net loss of $29.5M. The company focuses on oral, non-statin medicines for cardiovascular disease, with lead products NEXLETOL and NEXLIZET. Regulatory approvals and clinical trial results support product efficacy. Strategic initiatives include a royalty purchase agreement and capital management. Challenges include financial performance, market competition, and regulatory risks.